GlassScriptPhysician profile
Avinash P Ramdass
NPI 1184911372
$10,060.99
in general payments reported to CMS, 2019-2025
44 companies · $3,498 in 2025
The $3,498 reported for 2025 was more than what 85% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $343 · 2020: $172 · 2021: $506 · 2022: $954 · 2023: $2,317 · 2024: $2,271 · 2025: $3,498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,887 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,887.44 |
| Education | $198.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,031.81 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $1,033.15 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Aop Health US, LLC | $972.82 | 2025 | Rapiblyk |
| Actelion Pharmaceuticals US, INC. | $620.77 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $556.35 | 2019-2025 | Ofev, Stiolto Respimat |
| Regeneron Healthcare Solutions, INC. | $443.48 | 2020-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $395.07 | 2022-2025 | Zerbaxa, Recarbrio, Winrevair |
| Mylan Specialty L.P. | $309.98 | 2019-2024 | Yupelri, Yupelri |
| Mallinckrodt Hospital Products INC. | $294.07 | 2021-2024 | Acthar, Terlivaz |
| Genzyme Corporation | $289.95 | 2023-2025 | |
| Insmed, INC. | $288.85 | 2021-2025 | Arikayce, Brinsupri |
| Ani Pharmaceuticals, INC. | $279.55 | 2024-2025 | Purified Cortrophin Gel |
| Ethicon INC. | $211.72 | 2024 | Monarch Platform |
| United Therapeutics Corporation | $199.95 | 2021-2025 | Tyvaso, Tyvaso |
| Inspire Medical Systems, INC. | $192.40 | 2023-2025 | Inspire |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $188.62 | 2022-2025 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $174.81 | 2022-2024 | Glassia, Hyqvia |
| Inogen, INC. | $174.02 | 2022-2024 | Inogen |
| Pulmonx Corporation | $146.47 | 2023 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Viatris Specialty LLC | $140.93 | 2025 | Yupelri |
| Amgen INC. | $136.06 | 2021-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $130.58 | 2019-2024 | |
| Axsome Therapeutics, INC. | $111.74 | 2023-2025 | Sunosi |
| La Jolla Pharmaceutical Company | $91.12 | 2021 | |
| Shionogi INC | $88.48 | 2024-2025 | Fetroja |
| Jazz Pharmaceuticals INC. | $85.89 | 2023-2024 | |
| Avadel Cns Pharmaceuticals, LLC | $56.31 | 2024-2025 | Lumryz |
| Bayer Healthcare Pharmaceuticals INC. | $43.84 | 2019-2022 | |
| Baxter Healthcare | $43.74 | 2022-2024 | Hillrom - Vest System Model 105 Home Care |
| Electromed, INC. | $40.92 | 2025 | Smartvest |
| Abbvie INC. | $34.01 | 2024-2025 | |
| Philips North America LLC | $31.11 | 2021 | |
| Genentech USA, INC. | $29.60 | 2019-2024 | Xolair |
| Ambu INC. | $26.78 | 2023 | |
| Breas Medical, INC. | $26.02 | 2023 | Vivo 45 Ls |
| Lilly USA, LLC | $19.34 | 2025 | Zepbound |
| Circassia INC. | $18.23 | 2019 | |
| Fisher & Paykel Healthcare INC | $17.57 | 2024 | Fisher & Paykel Healthcare |
| Boston Scientific Corporation | $17.08 | 2023 | Exalt Model D |
| Idorsia Pharmaceuticals US INC | $15.26 | 2023 | Quviviq |
| Paratek Pharmaceuticals, INC. | $14.91 | 2022 | |
| Chiesi USA, INC. | $13.68 | 2020 | |
| Sunovion Pharmaceuticals INC. | $12.01 | 2019 | |
| Advanced Respiratory, INC | $11.94 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Avinash Ramdass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.